Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,999,786
  • Shares Outstanding, K 165,720
  • Annual Sales, $ 2,316 M
  • Annual Income, $ 259,000 K
  • 60-Month Beta 0.51
  • Price/Sales 4.76
  • Price/Cash Flow 17.54
  • Price/Book 5.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.93
  • Growth Rate Est. (year over year) +107,319.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.54 +25.84%
on 08/31/20
73.50 -1.48%
on 09/18/20
+11.48 (+18.84%)
since 08/18/20
3-Month
51.12 +41.65%
on 07/07/20
73.50 -1.48%
on 09/18/20
+19.12 (+35.88%)
since 06/18/20
52-Week
33.33 +117.25%
on 03/18/20
73.50 -1.48%
on 09/18/20
+34.33 (+90.15%)
since 09/18/19

Most Recent Stories

More News
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

RDY : 72.41 (+8.81%)
BMY : 59.27 (-0.22%)
EBS : 100.59 (-1.02%)
TECH : 243.90 (-0.54%)
Dr. Reddy's Laboratories announces settlement of U.S. Revlimid(R) (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the settlement of their litigation with Celgene,...

CELGZ : 0.47 (+2.15%)
RDY : 72.41 (+8.81%)
BMY : 59.27 (-0.22%)
Dr. Reddy's announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday(R), the Eye Allergy Drop in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter (OTC) Olopatadine...

RDY : 72.41 (+8.81%)
RDIF and Dr. Reddy's to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Dr. Reddy's Laboratories Ltd. (Dr. Reddy's), a global pharmaceutical company headquartered out of India, have agreed to cooperate...

RDY : 72.41 (+8.81%)
Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren(R) Arthritis Pain in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter Diclofenac Sodium...

RDY : 72.41 (+8.81%)
Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fulvestrant Injection, 250 mg/5 mL...

RDY : 72.41 (+8.81%)
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

TEVA : 9.48 (+2.05%)
RDY : 72.41 (+8.81%)
HZNP : 79.93 (+2.53%)
AMRN : 4.17 (-0.71%)
Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Methylphenidate Hydrochloride Extended-Release...

RDY : 72.41 (+8.81%)
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

RDY : 72.41 (+8.81%)
EBS : 100.59 (-1.02%)
ALIM : 5.70 (+1.60%)
TECH : 243.90 (-0.54%)
Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Penicillamine Capsules USP, 250 mg,...

RDY : 72.41 (+8.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 74.22
1st Resistance Point 73.31
Last Price 72.41
1st Support Level 71.69
2nd Support Level 70.98

See More

52-Week High 73.50
Last Price 72.41
Fibonacci 61.8% 58.16
Fibonacci 50% 53.42
Fibonacci 38.2% 48.67
52-Week Low 33.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar